Pertuzumab

Definition

A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)

Also known as 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, PERTUZUMAB, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Pertuzumab-dpzb, Poherdy, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440 — per NCIT

Also identified as

• ATC L01FD02 per RXNORM
• NCIT NCIT:C38692 per NCIT
• SCTID 704226002 per RXNORM
• SCTID 704227006 per RXNORM
• UNII K16AIQ8CTM per RXNORM

Indications